NASDAQ:NUVL Nuvalent (NUVL) Stock Forecast, Price & News $43.16 +0.54 (+1.27%) (As of 02:55 PM ET) Add Compare Share Share Today's Range$42.19▼$43.4850-Day Range$41.11▼$49.8552-Week Range$15.56▼$50.58Volume304,116 shsAverage Volume280,274 shsMarket Capitalization$2.46 billionP/E RatioN/ADividend YieldN/APrice Target$48.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Nuvalent MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside14.5% Upside$48.60 Price TargetShort InterestBearish10.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.60Based on 3 Articles This WeekInsider TradingSelling Shares$1.05 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.12) to ($2.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.77 out of 5 starsMedical Sector799th out of 961 stocksPharmaceutical Preparations Industry377th out of 449 stocks 3.3 Analyst's Opinion Consensus RatingNuvalent has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.60, Nuvalent has a forecasted upside of 14.5% from its current price of $42.45.Amount of Analyst CoverageNuvalent has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.04% of the float of Nuvalent has been sold short.Short Interest Ratio / Days to CoverNuvalent has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.Change versus previous monthShort interest in Nuvalent has recently decreased by 2.40%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNuvalent does not currently pay a dividend.Dividend GrowthNuvalent does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NUVL. Previous Next 1.9 News and Social Media Coverage News SentimentNuvalent has a news sentiment score of -0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Nuvalent this week, compared to 1 article on an average week.Search Interest3 people have searched for NUVL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added Nuvalent to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nuvalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,051,270.00 in company stock.Percentage Held by Insiders14.77% of the stock of Nuvalent is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.26% of the stock of Nuvalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nuvalent are expected to decrease in the coming year, from ($2.12) to ($2.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvalent is -22.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvalent is -22.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvalent has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nuvalent (NASDAQ:NUVL) StockNuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Read More NUVL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NUVL Stock News HeadlinesSeptember 18, 2023 | markets.businessinsider.comNuvalent (NUVL) Receives a Buy from Piper SandlerSeptember 18, 2023 | finance.yahoo.comNuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC SymposiumSeptember 21, 2023 | UNKNOWN (Ad)Out Of This World Stock Alerts!There Is This One Lithium Stock That Has Our Full Attention! Sign Up And Learn More!September 12, 2023 | americanbankingnews.comNuvalent's (NUVL) "Outperform" Rating Reaffirmed at WedbushSeptember 10, 2023 | finance.yahoo.comWe're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash WiselySeptember 5, 2023 | finance.yahoo.comNuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid TumorsAugust 31, 2023 | finance.yahoo.comNuvalent to Participate in Upcoming September Investor ConferencesAugust 10, 2023 | finanznachrichten.deNuvalent, Inc.: Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial ResultsSeptember 21, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.August 10, 2023 | finance.yahoo.comNuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | msn.comSVB Leerink Initiates Coverage of Nuvalent Inc - (NUVL) with Market Perform RecommendationAugust 8, 2023 | markets.businessinsider.comExpert Ratings for NuvalentAugust 1, 2023 | finance.yahoo.comNuvalent to Participate in Upcoming August Investor ConferencesJuly 25, 2023 | msn.comGuggenheim Initiates Coverage of Nuvalent Inc - (NUVL) with Buy RecommendationJuly 21, 2023 | finance.yahoo.comRecent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's WhyJuly 6, 2023 | msn.comNuvalent Inc - (NUVL) Price Target Increased by 6.95% to 51.00June 7, 2023 | finance.yahoo.comNuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's WhyMay 25, 2023 | msn.comNuvalent: Good Medicine, But Futuristic ValuationMay 24, 2023 | finance.yahoo.comNuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation SummitMay 12, 2023 | msn.comNuvalent: Q1 Earnings InsightsMay 11, 2023 | finance.yahoo.comNuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial ResultsApril 19, 2023 | finance.yahoo.comNuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology DaysApril 18, 2023 | finance.yahoo.comNuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023April 5, 2023 | nasdaq.comNuvalent Breaks Below 200-Day Moving Average - Notable for NUVLApril 2, 2023 | finance.yahoo.comNuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its BusinessMarch 23, 2023 | finance.yahoo.comNuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)March 17, 2023 | markets.businessinsider.comBMO Capital Keeps Their Buy Rating on Nuvalent (NUVL)See More Headlines Receive NUVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter. Email Address NUVL Company Calendar Last Earnings8/10/2023Today9/21/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NUVL CUSIPN/A CIK1861560 Webwww.nuvalent.com Phone857-357-7000FaxN/AEmployees78Year FoundedN/APrice Target and Rating Average Stock Price Forecast$48.60 High Stock Price Forecast$56.00 Low Stock Price Forecast$42.00 Forecasted Upside/Downside+13.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,850,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-25.59% Return on Assets-24.50% Debt Debt-to-Equity RatioN/A Current Ratio21.01 Quick Ratio21.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.59 per share Price / Book4.47Miscellaneous Outstanding Shares57,030,000Free Float48,602,000Market Cap$2.44 billion OptionableNot Optionable Beta1.35 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. James R. Porter Ph.D. (Age 47)CEO, Pres & Director Comp: $998.02kProf. Matthew D. Shair Ph.D. (Age 54)Founder, Head of Scientific Advisory Board & Director Comp: $235kMs. Alex Balcom CPA (Age 38)M.B.A., CFO & Treasurer Comp: $654.22kDr. Christopher D. Turner M.D. (Age 54)Chief Medical Officer Comp: $714.26kDr. Benjamin LaneSr. VP of Technical OperationsMs. Deborah Ann Miller J.D. (Age 47)Ph.D., Chief Legal Officer & Sec. Mr. Matthew MetivierVP of HRMs. Darlene Noci (Age 46)Chief Devel. Officer Mr. Henry Pelish Ph.D.Sr. VP of Drug DiscoveryMr. John Soglia Ph.D.Sr. VP of Translational Devel.More ExecutivesKey CompetitorsMorphicNASDAQ:MORFZai LabNASDAQ:ZLABMaravai LifeSciencesNASDAQ:MRVIUltragenyx PharmaceuticalNASDAQ:RAREXenon PharmaceuticalsNASDAQ:XENEView All CompetitorsInsiders & InstitutionsDeborah Ann MillerSold 2,000 sharesTotal: $95,280.00 ($47.64/share)Darlene NociSold 3,000 sharesTotal: $139,680.00 ($46.56/share)Perceptive Advisors LLCSold 105,227 shares on 8/24/2023Ownership: 3.863%California State Teachers Retirement SystemSold 1,608 shares on 8/21/2023Ownership: 0.046%Nuveen Asset Management LLCBought 4,402 shares on 8/16/2023Ownership: 0.107%View All Insider TransactionsView All Institutional Transactions NUVL Stock - Frequently Asked Questions Should I buy or sell Nuvalent stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVL shares. View NUVL analyst ratings or view top-rated stocks. What is Nuvalent's stock price forecast for 2023? 6 analysts have issued 12 month price targets for Nuvalent's stock. Their NUVL share price forecasts range from $42.00 to $56.00. On average, they expect the company's share price to reach $48.60 in the next twelve months. This suggests a possible upside of 13.5% from the stock's current price. View analysts price targets for NUVL or view top-rated stocks among Wall Street analysts. How have NUVL shares performed in 2023? Nuvalent's stock was trading at $29.78 at the beginning of 2023. Since then, NUVL stock has increased by 43.8% and is now trading at $42.82. View the best growth stocks for 2023 here. When is Nuvalent's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our NUVL earnings forecast. How were Nuvalent's earnings last quarter? Nuvalent, Inc. (NASDAQ:NUVL) announced its earnings results on Thursday, August, 10th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.04. What ETFs hold Nuvalent's stock? ETFs with the largest weight of Nuvalent (NASDAQ:NUVL) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco DWA SmallCap Momentum ETF (DWAS). When did Nuvalent IPO? (NUVL) raised $151 million in an IPO on Thursday, July 29th 2021. The company issued 8,900,000 shares at $16.00-$18.00 per share. What is Nuvalent's stock symbol? Nuvalent trades on the NASDAQ under the ticker symbol "NUVL." Who are Nuvalent's major shareholders? Nuvalent's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.22%), Perceptive Advisors LLC (3.86%), Driehaus Capital Management LLC (2.54%), State Street Corp (2.06%), Commodore Capital LP (2.02%) and Geode Capital Management LLC (0.93%). Insiders that own company stock include Christopher Durant Turner, Darlene Noci, Deborah Ann Miller and Matthew Shair. View institutional ownership trends. How do I buy shares of Nuvalent? Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nuvalent's stock price today? One share of NUVL stock can currently be purchased for approximately $42.82. How much money does Nuvalent make? Nuvalent (NASDAQ:NUVL) has a market capitalization of $2.44 billion. The company earns $-81,850,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. How can I contact Nuvalent? The official website for the company is www.nuvalent.com. The company can be reached via phone at 857-357-7000 or via email at ir@nuvalent.com. This page (NASDAQ:NUVL) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.